The impact of high-risk patients on the results of clinical trials

Journal of Clinical Epidemiology

Volumn 50, Issue 10, 1997, Pages 1089-1098

  Ioannidis, John P A ^a,b,c   Lau, Joseph ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HIV   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Acute myocardial infarction; AIDS; Heterogeneity; HIV; Magnesium; Mathematical modeling; Mega trials; Meta analysis; Randomized controlled trials

Indexed keywords

MAGNESIUM;

ACUTE HEART INFARCTION; CLINICAL TRIAL; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; PRIORITY JOURNAL; REVIEW;

EID: 0030668793     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(97)00149-2     Document Type: Article

References (67)

1. Bailey KR. Generalizing the results of randomized clinical trials. Control Clin Trials 1994; 15: 15-23.
2. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet 1995; 345: 1616-1619.
3. Mocroft AJ, Johnson MA, Sabin CA, et al. Staging system for clinical AIDS patients: Royal Free/Chelsea and Westminster Hospital Collaborative Group. Lancet 1995; 345: 12-17.
4. Ioannidis JPA, Cappelleri JC, Lau J, Sacks HS, Skolnik PR. Predictive value of viral load measurements in asymptomatic untreated HIV-1 infection: A mathematical model. AIDS 1996; 10: 255-262.
5. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-579.
6. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-1170.
7. Ho DD. Viral counts count in HIV infection. Science 1996; 272: 1124-1125.
8. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Med 1996; 2: 405-411.
9. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996; 273: 1856-1862.
10. Mocroft A, Johnson MA, Phillips AN. Factors affecting survival in patients with the acquired immunodeficiency syndrome. AIDS 1996; 10: 1057-1065.
11. Darby SC, Ewart DW, Giangrande PLF, et al. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet 1996; 347: 1573-1579.
12. Phillips AN, Elford J, Sabin C, Bofill M, Janossy G, Lee CA. Immunodeficiency and the risk of death in HIV infection. JAMA 1992; 268: 2662-2666.
13. Lemp GF, Payne SF, Neal D, Temelso T, Rutherford GW. Survival trends for patients with AIDS. JAMA 1990; 263: 402-604.
14. Cameron B, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. Program and Abstracts of the Third National Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 28-February 1, 1996. (Abstract LB6a)
15. Delta Coordinating Committee. Delta: A randomised doubleblind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-291.
16. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081-1090.
17. Montaner J, Cooper D, Katlama C, et al. CAESAR: Confirmation of the clinical benefit of 3TC in HIV-1 disease: Preliminary results. Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 15-18, 1996. (Abstract LB6)
18. Salgo MP, Beattie D, Bragman K, et al. Saquinavir vs. zalcitabine vs. combination as treatment for advanced HIV infection in patients discontinuing/unable to take zidovudine. Program and Abstracts of the XI International Conference on AIDS. Vancouver, British Columbia, July 7-12, 1996. (Abstract No. B.410)
19. Concorde Coordinating Committee. Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-881.
20. Fischl MA, Stanley K, Collier AC, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995; 122: 24-32.
21. Ioannidis JPA, Cappelleri JC, Lau J, et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness: A meta-analysis. Ann Intern Med 1995; 122: 856-866.
22. Egger M, Neaton JD, Phillips AN, Davey Smith G. Concorde trial of immediate versus deferred zidovudine. Lancet 1994; 343: 1355. (Letter)
23. Saint-Marc T, Touraine JL, Berra N. Beneficial effects of intravenous immunoglobulins in AIDS. Lancet 1992; 340: 1347. (Letter)
24. Jacobson MA, Causey D, Polsky B, et al. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J Infect Dis 1993; 168: 444-448.
25. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex: A randomized, double-blind, dose-ranging study in patients with AIDS: AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994; 121: 905-911.
26. Chaisson RE, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997; 11: 311-317.
27. Youle M, Gazzard BG, Johnson MA, et al. Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: A double-blind, placebo-controlled study. AIDS 1994; 8: 641-649.
28. Salmon-Ceron D, Fontbonne A, Saba J, et al. Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. J Infect Dis 1995; 172: 656-664.
29. Schooley RT, Ramirez-Ronda C, Lange JMA, et al. Virologic and immunologic benefits of in itial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis 1996; 173: 1354-1366.
30. Dieterich D for the SOCA Research Group. Monoclonal antibody CMV retinitis trial: Preliminary results. Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 15-18, 1996. (Abstract LB8b)
31. Cohn D, Fisher E, Franchino B, et al. A prospective, randomized trial of four 3-drug regimens for treatment of disseminated MAC disease in AIDS: Excess mortality associated with high-dose clarithromycin. Program and Abstracts of the Fourth National Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-26, 1996. (Abstract 659)
32. Sattler FR, Frame P, Davis R, et al. Trimetrexate with leukovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: A prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031. J Infect Dis 1994; 170: 165-172.
33. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind placebo-controlled trial. N Engl J Med 1987; 317: 185-191.
34. Hughes WT, Leoung G, Kramer F, et al. Comparison of atovaquone and trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993; 328: 1521-1527.
35. Jacobson M, Besch CL, Child C, et al. Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with human immunodeficiency virus disease: Results of a randomized trial. J Infect Dis 1994; 169: 384-394.
36. Studies of Ocular Complications of AIDS Research Group, in Collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immune deficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326: 213-220.
37. Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323: 1451-1457.
38. Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: Rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996; 335: 377-383.
39. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335: 384-391.
40. Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, La-Voie L. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: A double-blind, placebo-controlled trial. N Engl J Med 1990; 323: 1444-1450.
41. Cooper DA, Pehrson PO, Pedersen C, et al. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: A double-blind, randomised trial. AIDS 1993; 7: 197-207.
42. 3). Program and Abstracts of the Fourth National Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-26, 1997. (Abstract LB6)
43. Smith GD, Song F, Sheldon RA. Cholesterol lowering and mortality: The importance of considering initial level of risk. BMJ 1993; 306: 1367-1373.
44. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. BMJ 1995; 311: 1356-1359.
45. Boissel JP, Collet JP, Lievre M, Girard P. An effect model for the assessment of drug benefit: Example of antiarrhythmic drugs in postmyocardial infarction patients. J Cardiovasc Pharmacol 1993; 22: 356-363.
46. Thompson SG. Controversies in meta-analysis: The case of the trials of serum cholesterol reduction. Stat Meth Med Res 1993; 2: 173-192.
47. McIntosh M. The population risk as an explanatory variable in research synthesis of clinical trials. Stat Med 1996; 15: 1713-1728.
48. ISIS-4 Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
49. Teo KK, Yusuf S, Collins R, Held PH, Peto R. Effects of intravenous magnesium in suspected acute myocardial infarction: Overview of randomised trials. BMJ 1991; 303: 1499-1503.
50. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: Results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339: 1553-1558.
51. Egger M, Smith GD. Misleading meta-analysis: Lessons from "an effective, safe, simple" intervention that wasn't. BMJ 1995; 310: 752-754.
52. Woods KL. Mega-trials and management of acute myocardial infarction. Lancet 1995; 346: 611-614.
53. Lee KL, Woodlief LH, Topol EJ. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarct on. Circulation 1995; 91: 1659-1668.
54. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 248-254.
55. Antman E. Randomized trials of magnesium in acute myocardial infarction: Big numbers do not tell the whole story. Am J Cardiol 1995; 75: 391-393.
56. Baxter GF, Sumeray MS, Walker JM. Infarct size and magnesium: Insights into LIMIT-2 and ISIS-4 from experimental studies. Lancet 1996; 348: 1424-1426.
57. Leor J, Kloner RA. An experimental model examining the role of magnesium in the therapy of acute myocardial infarction. Am J Cardiol 1995; 75: 1292-1293.
58. Christiansen CW, Rieder MA, Silverstein EL, Gencheff NE. Magnesium sulfate reduces myocardial infarct size when administered before but not after coronary reperfusion in a canine model. Circulation 1995; 92: 2617-2621.
59. Herzog WR, Schlossberg ML, MacMurdy KS, et al. Timing of magnesium therapy affects experimental infarct size. Circulation 1995; 92: 2622-2626.
60. Collins R, Peto R, Sleight P, for the ISIS-4 Collaborative Group. ISIS-4. Lancet 1995; 345: 1374-1375. [Letter; Reply]
61. Hunink MGM, Goldman L, Tosteson ANA, et al. The recent decline in mortality from coronary heart disease, 1980-1990: The effect of secular trends in risk factors and treatment. JAMA 1997; 277: 535-542.
62. Immonen-Raiha P, Arstila M, Tuomilehto J, et al. 21-year trends in incidence of myocardial infarction and mortality from coronary disease in middle-age. Eur Heart J 1996; 17: 1495-1502.
63. Holmes DR, Califf RM, Van de Werf F, et al. Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: Results from the GUSTO trial. Lancet 1997; 349: 75-78.
64. Rubin D. Meta-analysis: Literature synthesis or effect-size surface estimation? J Educ Stat 1992; 17: 363-374.
65. Cappelleri JC, Ioannidis JPA, Schmid CH, et al. Large trials vs. meta-analysis of smaller trials: How do their results compare? JAMA 1996; 276: 1332-1338.
66. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344: 563-570.
67. Ioannidis JPA, Cappelleri JC, Schmid CH, Lau J. Impact of epidemic and individual heterogeneity on the population distribution of disease progression rates: An example from patient populations in trials of human immunodeficiency virus infection. Am J Epidemiol 1996; 144: 1074-1085.